CRI Logo
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Types
    • Cancer Types
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact
Donate

Immune to Cancer: The CRI Blog

  • CICON19 Day 1 Update: Cancer Prevention and Combination Immunotherapy Strategies

    Day 1 of CICON19 explored how checkpoint immunotherapy might be improved through combination strategies as well as…

    September 25, 2019| Arthur N. Brodsky, PhD
  • CICON19 Preview: Translating Science into Survival

    Topics at the upcoming CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CICON19) in Paris include prevention, the tumor microenvironment,…

    September 16, 2019| Arthur N. Brodsky, PhD
  • CICON18 Day 4 Update: The Role of Bacteria; Technologies to Advance Cancer Immunotherapy

    The final day of CICON18 explored two diverse areas—technology and the microbiome—that both have the…

    October 4, 2018| Arthur N. Brodsky, PhD
  • CICON18 Day 3 Update: Targeting Tumor Mutations with Vaccine-Based Immunotherapies

    The third day of CICON18 explored cutting-edge strategies to identify and target the mutated markers that distinguish…

    October 3, 2018| Arthur N. Brodsky, PhD
  • CICON18 Preview: Translating Science into Survival

    Highlights from the upcoming International Cancer Immunotherapy Conference (CICON18), including regulating T cell response, tackling the tumor…

    September 26, 2018| Arthur N. Brodsky, PhD
  • CICON17 Day 4 Recap: The Tumor Microenvironment and Oncolytic Viruses

    The final day of CICON17 explored two newer immunotherapy approaches that reflect broader understanding of tumor-immune interactions…

    September 10, 2017| Arthur N. Brodsky, PhD
  • CICON17 Day 3 Recap: Combinations, Checkpoint Immunotherapy Resistance, Immunomodulators, and Microbiota

    Day 3 of the CICON17 focused on combination therapies, immunomodulators, overcoming immune suppression, and the role bacteria in…

    September 9, 2017| Arthur N. Brodsky, PhD
  • CICON17 Day 2 Recap: Biomarkers, Novel Agents, and Adoptive Cell Therapies

    Day 2 of CICON17 offered a focused exploration of the latest discoveries and data from scientific studies…

    September 8, 2017| Arthur N. Brodsky, PhD
  • Video: Watch These Facebook Live Updates on Cancer Immunotherapy with CRI Experts

    CRI CEO and Director of Scientific Affairs Jill O’Donnell-Tormey, PhD, appeared in two informative Facebook Live broadcasts…

    October 7, 2016| Kat Noel
Previous Page
1 2 3 4
Next Page

Cancer Research Institute
29 Broadway, Floor 4

New York, NY  10006-3111

Facebook Icon
X icon
YouTube icon
LinkedIn icon
Instagram icon
Threads icon
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Type
    • Cancer Type
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Donate
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact

Uniting for a World Immune to Cancer

  • Accessibility Statement
  • Privacy Policy
  • Terms & Conditions
  • Site Map

*Immunotherapy results may vary from patient to patient.

©2025, Cancer Research Institute